New therapy approved to treat severe equine asthma

0
382
equine asthma

Recently the European Commission granted marketing authorisation to Boehringer Ingelheim for its new Aservo® EquiHaler®—developed for horses that suffer from severe equine asthma.

Affected horses struggle to breathe, even at rest, and stand to greatly benefit from this new therapy.

While inhaled therapies for the treatment of asthma are common in human health, the approval of the Aservo® EquiHaler® marks an industry first in equine medicine, as until now, there has been no approved corticosteroid inhalant therapy licensed for use in horses with severe equine asthma.

The Aservo® EquiHaler® represents the culmination of over a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. 

The Respimat™ inhaler used in human respiratory disease is differentiated by the unique Soft Mist™ Technology, which was integrated into the new Aservo® EquiHaler®, allowing medication to be inhaled, deep into the lung. 

The newly approved inhaler is designed specifically for use in horses. It includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adaptor that fits gently inside the nostril of the horse, allowing the horses to easily inhale the medicated mist. 

The active ingredient in the Aservo® EquiHaler® is the prodrug ciclesonide, which is a corticosteroid that is activated directly in the lung, reducing lower airway inflammation associated with severe equine asthma.

“Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breathe,” said Erich Schoett, global business head of Equine for the Boehringer Ingelheim Animal Health Business Unit.

“Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here